These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 6766550)

  • 1. [Is sodium valproate bioavailability only altered by food intake?].
    Bruguerolle B; Valli M; Jadot G; Bouyard L; Bouyard P
    Nouv Presse Med; 1980 Jan; 9(1):44. PubMed ID: 6766550
    [No Abstract]   [Full Text] [Related]  

  • 2. [Bioavailability of sodium valproate is modified by diet].
    Loiseau P; Cenraud B; Morselli PL; Brachet-Liermain A
    Nouv Presse Med; 1979 Jun; 8(26):2202-3. PubMed ID: 382109
    [No Abstract]   [Full Text] [Related]  

  • 3. [On the enteral absorption of valproic acid (author's transl)].
    Oelkers W; Stoffels G; Schäfer H; Reith H
    Arzneimittelforschung; 1977; 27(5):1088-90. PubMed ID: 328020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of food on the pharmacokinetics of a new multiple unit sustained release sodium valproate formulation.
    Retzow A; Vens-Cappell B; Wangemann M
    Arzneimittelforschung; 1997 Dec; 47(12):1347-50. PubMed ID: 9450162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability of valproate after gastric and direct intestinal administration in rats.
    Yeomans ND; Vajda FJ; Baldas J
    Clin Exp Pharmacol Physiol; 1982; 9(2):173-7. PubMed ID: 6813007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of food on valproic acid absorption.
    Hamilton RA; Garnett WR; Kline BJ; Pellock JM
    Am J Hosp Pharm; 1981 Oct; 38(10):1490-3. PubMed ID: 6794365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and bioavailability of sodium valproate.
    Klotz U; Antonin KH
    Clin Pharmacol Ther; 1977 Jun; 21(6):736-43. PubMed ID: 324695
    [No Abstract]   [Full Text] [Related]  

  • 8. Non-equivalence of bioavailability between generic and branded form of sodium valproate.
    Dhanaraj M; Jayavelu A
    Neurol India; 2004 Sep; 52(3):398. PubMed ID: 15472447
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of three antacids on the bioavailability of valproic acid.
    May CA; Garnett WR; Small RE; Pellock JM
    Clin Pharm; 1982; 1(3):244-7. PubMed ID: 6821035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
    Wangemann M; Retzow A; Vens-Cappell B
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonlinear elimination and cholerteic effect of valproic acid in the monkey.
    Dickinson RG; Taylor SM; Kaufman SN; Rodgers RM; Lynn RK; Gerber N; Baughman WL
    J Pharmacol Exp Ther; 1980 Apr; 213(1):38-48. PubMed ID: 6767022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a rat model of valproate-induced obesity.
    Wolden-Hanson T; Gidal BE; Atkinson RL
    Pharmacotherapy; 1998; 18(5):1075-81. PubMed ID: 9758318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers.
    Kulkarni C; Vaz J; David J; Joseph T
    Indian J Physiol Pharmacol; 1995 Apr; 39(2):122-6. PubMed ID: 7649598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of the two-compartment open model with Michaelis-Menten elimination kinetics to valproic acid in the bile-exteriorized rat.
    Lawyer CH; Gerber N; Lynn RK; Dickinson RG
    Res Commun Chem Pathol Pharmacol; 1980 Mar; 27(3):469-84. PubMed ID: 6770426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aluminum bioavailability from the approved food additive leavening agent acidic sodium aluminum phosphate, incorporated into a baked good, is lower than from water.
    Yokel RA; Florence RL
    Toxicology; 2006 Oct; 227(1-2):86-93. PubMed ID: 16949191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative bioavailability of different valproic acid formulations.
    Franke G; Diletti E; Hoffmann C; Zschiesche M; Scheuch E; Siegmund W
    Int J Clin Pharmacol Ther; 1995 Dec; 33(12):653-7. PubMed ID: 8963482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absorption rate and bioavailability of valproic acid and its sodium from rectal dosage forms.
    Moolenaar F; Greving WJ; Huizinga T
    Eur J Clin Pharmacol; 1980 Apr; 17(4):309-15. PubMed ID: 6772450
    [No Abstract]   [Full Text] [Related]  

  • 18. Sodium valproate.
    Kupferberg HJ
    Adv Neurol; 1980; 27():643-54. PubMed ID: 6769305
    [No Abstract]   [Full Text] [Related]  

  • 19. Sodium valproate inhibits glucose transport and exacerbates Glut1-deficiency in vitro.
    Wong HY; Chu TS; Lai JC; Fung KP; Fok TF; Fujii T; Ho YY
    J Cell Biochem; 2005 Nov; 96(4):775-85. PubMed ID: 16149077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability of valproate sodium syrup in various unit dose containers.
    Sartnurak S; Christensen JM
    Am J Hosp Pharm; 1982 Apr; 39(4):627-9. PubMed ID: 6805320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.